Keyphrases
Large B-cell Lymphoma
100%
Cell Infusion
100%
Anti-CD19 chimeric Antigen Receptor T Cells
100%
Molecular Response
75%
Chimeric Antigen Receptor T Cells (CAR-T)
50%
Axicabtagene Ciloleucel
50%
Immune Effector Cell-associated Neurotoxicity Syndrome (ICANS)
50%
CD8+ T Cells
25%
Complete Response
25%
Adverse Events
25%
Clinical Response
25%
Progressive Disease
25%
Partial Response
25%
Transcriptomics
25%
Positron Emission Tomography-computed Tomography (PET-CT)
25%
CD19
25%
Monocytes
25%
CD8+ T Cell Exhaustion
25%
High Efficacy
25%
Molecular Features
25%
Long-term Remission
25%
3-month Follow-up
25%
Transcriptional Features
25%
Early Predictors
25%
Cell Identification
25%
Cell-free DNA Screening
25%
Single-cell RNA Sequencing (scRNA-seq)
25%
Rare Cell Population
25%
Chimeric Antigen Receptor T-cell Therapy
25%
Medicine and Dentistry
Infusion
100%
Large-Cell Lymphoma
100%
Chimeric Antigen Receptor T-Cell
100%
Immunity
50%
Effector Cell
50%
Cytotoxic T-Cell
50%
Axicabtagene Ciloleucel
50%
Toxicity and Intoxication
50%
Progressive Disease
25%
Adverse Event
25%
Positron Emission Tomography-Computed Tomography
25%
Cell Population
25%
Transcriptomics
25%
RNA Sequence
25%
Cell-Free DNA
25%
Chimeric Antigen Receptor T-Cell Immunotherapy
25%
DNA Sequencing
25%